Impact of Glycine Powder Air‐Abrasive Debridement on Peri‐Implant Mucositis: A Randomized Control Trial of Clinical, Microbial, and Immunological Changes
Clinical Oral Implants Research · 2025
DOI: 10.1111/clr.14361 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Oral Implants Research, 2025. Verfasst von Brian Partido und 2 weiteren Autor:innen. Beteiligte Einrichtung: Dental Programs, Healthcare and Human Services Division, Seattle Central Health Education Center, Seattle, Washington, USA. Hauptthemen laut MEDLINE: Glycine, Powders. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIDCR NIH HHS, Delta Dental Foundation, Colgate-Palmolive Company.
Abstract (Originalsprache)
Aim
Peri‐implant mucositis, a dysbiosis‐driven inflammatory disease, is a precursor to peri‐implantitis, underscoring the need for early disease management. Therefore, we investigated the efficacy of glycine powder in resolving clinical inflammation and restoring host‐microbial homeostasis.
Methods
Thirty subjects were randomized to receive either glycine powder air‐abrasive debridement or ultrasonic instrumentation. Clinical parameters (probe depth [PD], modified Sulcular Bleeding Index [mSBI], modified Plaque Index [mPlI]), biofilm and peri‐implant crevicular fluid were collected at baseline and at 1‐day, 1‐, 3‐, 6‐weeks and 3‐ and 6‐months post‐therapy. Microbial recolonization was examined using 16S rDNA sequencing and immune response was semi‐quantified using a bead‐based 17‐plex microarray.
Results
At 6‐months, both groups demonstrated non‐significant reductions in mSBI when compared to baseline ( p > 0.05, Wald test, mixed model for repeated measures). However, mSBI and PD decreased in the test group from week‐1 to 3‐months, while control group decreased at 1‐ and 3‐weeks only. mSBI was lower in the test group when compared to controls from Week‐1 to 3‐months, while PD differed between groups at 6 weeks and 3‐months. Glycine group demonstrated significant microbial shifts after 24‐h, increases in species richness and health‐compatible species, and loss of pathobionts ( p < 0.001, Dunn test). Pro‐inflammatory cytokines decreased from 1‐ to 6‐weeks or 3‐months ( p < 0.05, Wald test). Comparable results were obtained in the ultrasonic group at 3‐weeks and sustained over 6‐weeks post‐therapy.
Conclusions
Glycine therapy leads to early and sustained change in host‐microbial interactions when compared to ultrasonics, however, the changes wrought by both therapies were sustained for a maximum of 3 months. Trial Registration ClinicalTrials.gov identifier: NCT05810558
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Dental Programs, Healthcare and Human Services Division, Seattle Central Health Education Center, Seattle, Washington, USA.
- James Cancer Institute and Solove Research Center, The Ohio State University, Columbus, Ohio, USA.
- Department of Periodontics and Oral Medicine, University of Michigan, Ann Arbor, Michigan, USA.
ORCID-Profile: Purnima S Kumar
Förderung
- NIDCR NIH HHS
- Delta Dental Foundation
- Colgate-Palmolive Company
- National Institute of Dental and Craniofacial Research
Zitieren
APA
Partido, B., Saraswat, S., & Kumar, P. S. (2025). Impact of Glycine Powder Air‐Abrasive Debridement on Peri‐Implant Mucositis: A Randomized Control Trial of Clinical, Microbial, and Immunological Changes. Clinical Oral Implants Research. https://doi.org/10.1111/clr.14361
Vancouver
Partido B, Saraswat S, Kumar PS. Impact of Glycine Powder Air‐Abrasive Debridement on Peri‐Implant Mucositis: A Randomized Control Trial of Clinical, Microbial, and Immunological Changes. Clinical Oral Implants Research. 2025. doi:10.1111/clr.14361
BibTeX
@article{Partido2025,
author = {Partido, Brian and Saraswat, Shweta and Kumar, Purnima S},
title = {Impact of Glycine Powder Air‐Abrasive Debridement on Peri‐Implant Mucositis: A Randomized Control Trial of Clinical, Microbial, and Immunological Changes},
journal = {Clinical Oral Implants Research},
year = {2025},
doi = {10.1111/clr.14361}
}
EUVIMED